Skip to content

Rituximab and Hyaluronidase Human

BIOLOGICAL13 trials

Sponsors

ECOG-ACRIN Cancer Research Group, Emory University, Fred Hutchinson Cancer Center, Thomas Jefferson University, Academic and Community Cancer Research United

Conditions

Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaBurkitt LymphomaClassic Follicular LymphomaCutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVDiffuse Large B-Cell Lymphoma

Phase 1

Phase 2

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Active, not recruitingNCT03719131
Emory UniversityCutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage IIIA Skin Melanoma +5
Start: 2019-06-05End: 2026-06-30Updated: 2025-04-22
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Active, not recruitingNCT04626791
Academic and Community Cancer Research UnitedMantle Cell Lymphoma
Start: 2021-08-03End: 2028-08-03Updated: 2026-08-25
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
TerminatedNCT04659044
Academic and Community Cancer Research UnitedRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma +11
Start: 2021-04-01End: 2024-03-29Updated: 2024-09-19
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Active, not recruitingNCT04799275
National Cancer Institute (NCI)Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma +18
Start: 2021-05-20End: 2027-03-01Target: 422Updated: 2026-07-08
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
RecruitingNCT05886036
National Cancer Institute (NCI)Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
Start: 2024-01-23End: 2026-10-31Target: 70Updated: 2026-08-31
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Not yet recruitingNCT07724457
National Cancer Institute (NCI)Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma +1
Start: 2026-10-30End: 2033-11-01Target: 271Updated: 2026-08-19

Phase 3

Related Papers